-DOCSTART- -X- O
Exacerbations -X- _ B-Patient
of -X- _ I-Patient
chronic -X- _ I-Patient
obstructive -X- _ I-Patient
pulmonary -X- _ I-Patient
disease -X- _ I-Patient
( -X- _ I-Patient
COPD -X- _ I-Patient
) -X- _ I-Patient
are -X- _ O
important -X- _ O
events -X- _ O
that -X- _ O
carry -X- _ O
significant -X- _ O
consequences -X- _ O
for -X- _ O
patients. -X- _ O
Some -X- _ O
patients -X- _ O
experience -X- _ O
frequent -X- _ O
exacerbations -X- _ O
, -X- _ O
and -X- _ O
are -X- _ O
now -X- _ O
recognized -X- _ O
as -X- _ O
a -X- _ O
distinct -X- _ O
clinical -X- _ O
subgroup -X- _ O
, -X- _ O
the -X- _ O
‘frequent -X- _ O
exacerbator’ -X- _ O
phenotype. -X- _ O
This -X- _ O
is -X- _ O
relatively -X- _ O
stable -X- _ O
over -X- _ O
time -X- _ O
, -X- _ O
occurs -X- _ O
across -X- _ O
disease -X- _ O
severity -X- _ O
, -X- _ O
and -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
poorer -X- _ O
health -X- _ O
outcomes. -X- _ O
These -X- _ O
patients -X- _ O
are -X- _ O
therefore -X- _ O
a -X- _ O
priority -X- _ O
for -X- _ O
research -X- _ O
and -X- _ O
treatment. -X- _ O
The -X- _ O
pathophysiology -X- _ O
underlying -X- _ O
the -X- _ O
frequent -X- _ O
exacerbator -X- _ O
phenotype -X- _ O
is -X- _ O
complex -X- _ O
, -X- _ O
with -X- _ O
increased -X- _ O
airway -X- _ O
and -X- _ O
systemic -X- _ O
inflammation -X- _ O
, -X- _ O
dynamic -X- _ O
lung -X- _ O
hyperinflation -X- _ O
, -X- _ O
changes -X- _ O
in -X- _ O
lower -X- _ O
airway -X- _ O
bacterial -X- _ O
colonization -X- _ O
and -X- _ O
a -X- _ O
possible -X- _ O
increased -X- _ O
susceptibility -X- _ O
to -X- _ O
viral -X- _ O
infection. -X- _ O
Frequent -X- _ B-Outcome
exacerbators -X- _ I-Outcome
are -X- _ I-Outcome
also -X- _ I-Outcome
at -X- _ I-Outcome
increased -X- _ I-Outcome
risk -X- _ I-Outcome
from -X- _ I-Outcome
comorbid -X- _ I-Outcome
extrapulmonary -X- _ I-Outcome
diseases -X- _ I-Outcome
including -X- _ I-Outcome
cardiovascular -X- _ I-Outcome
disease -X- _ I-Outcome
, -X- _ I-Outcome
gastroesophageal -X- _ I-Outcome
reflux -X- _ I-Outcome
, -X- _ I-Outcome
depression -X- _ I-Outcome
, -X- _ I-Outcome
osteoporosis -X- _ I-Outcome
and -X- _ I-Outcome
cognitive -X- _ I-Outcome
impairment. -X- _ I-Outcome
Overall -X- _ O
these -X- _ O
patients -X- _ B-Outcome
have -X- _ I-Outcome
poorer -X- _ I-Outcome
health -X- _ I-Outcome
status -X- _ I-Outcome
, -X- _ I-Outcome
accelerated -X- _ I-Outcome
forced -X- _ I-Outcome
expiratory -X- _ I-Outcome
volume -X- _ I-Outcome
over -X- _ I-Outcome
1 -X- _ I-Outcome
s -X- _ I-Outcome
( -X- _ I-Outcome
FEV1 -X- _ I-Outcome
) -X- _ I-Outcome
decline -X- _ I-Outcome
, -X- _ I-Outcome
worsened -X- _ I-Outcome
quality -X- _ I-Outcome
of -X- _ I-Outcome
life -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
increased -X- _ I-Outcome
hospital -X- _ I-Outcome
admissions -X- _ I-Outcome
and -X- _ I-Outcome
mortality -X- _ I-Outcome
, -X- _ I-Outcome
contributing -X- _ I-Outcome
to -X- _ I-Outcome
increased -X- _ I-Outcome
exacerbation -X- _ I-Outcome
susceptibility -X- _ I-Outcome
and -X- _ I-Outcome
perpetuation -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
frequent -X- _ I-Outcome
exacerbator -X- _ I-Outcome
phenotype. -X- _ I-Outcome
This -X- _ O
review -X- _ O
article -X- _ O
sets -X- _ O
out -X- _ O
the -X- _ O
definition -X- _ O
and -X- _ O
importance -X- _ O
of -X- _ O
the -X- _ O
frequent -X- _ O
exacerbator -X- _ O
phenotype -X- _ O
, -X- _ O
with -X- _ O
a -X- _ O
detailed -X- _ O
examination -X- _ O
of -X- _ O
its -X- _ O
pathophysiology -X- _ O
, -X- _ O
impact -X- _ O
and -X- _ O
interaction -X- _ O
with -X- _ O
other -X- _ O
comorbidities -X- _ O
. -X- _ O

